Celator® Pharmaceuticals Announces Expansion of Clinical Study in Patients with Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia

By: via Benzinga
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.